Sirtuin 1 ve Sirtuin 2’nin Tip 2 Diyabet ile İlişkisi
Diabetes mellitus, bütün dünyada ve bütün yaş gruplarında en sık görülen endokrin hastalıktır. Tip 2 diabet; diabet vakalarının yaklaşık %80-90’nı oluşturan ve tipik olarak ileri yaşlarda ortaya çıkan bir hastalıktır. Tip 2 diabet patogenezi oldukça karmaşıktır ve birçok yönden halen tartışma konusudur. Kalıtım poligeniktir ve çevresel faktörlerle güçlü bir ilişkisi mevcuttur. Bozulmuş insulin sekresyonu ve bozulmuş insulin sensitivitesi söz konusudur. Sirtuin ailesi (SIRT) NAD+ bağımlı deasetilazlar olup memelilerde, maya ve yüksek organizmalarda histon deasitalasyonu ve DNA stabilizasyonunu sağlar. Yapılan çalışmalarda onkogenez, uzun ömür, metabolik regülasyon ve nörodejeneratif hastalıklar ile ilişkili olduğu gösterilmiştir. Hücre döngüsünün düzenlenmesi, apoptoz, mitokondriyal biyogenez, lipid metabolizması, yağ asidi oksidasyonu, hücresel stres yanıtı, insülin salgılanması, yaşlanma ve inflamasyon gibi pek çok fizyolojik süreçte rol oynayan sirtuinlerin son yıllarda diyabet patogenezinde de oldukça önemli rolü olduğu tespit edilmiştir.
Relationship Between Sirtuin 1 and Sirtuin 2 with Type 2 Diabetes
Diabetes mellitus is the most common endocrine disease in the world and in all age groups. Type 2 diabetes is a disease that constitutes approximately 80-90% of diabetes cases and typically occurs in advanced ages. The pathogenesis of type 2 diabetes is quite complex and is still a matter of debate in many aspects. Heredity is polygenic and has a strong relationship with environmental factors. There is impaired insulin secretion and impaired insulin sensitivity. The Sirtuin family (SIRT) members are NAD+ dependent deacetylases that provide histone deacetylation and DNA stabilization in mammals, yeast and higher organisms. Studies have shown that it is associated with oncogenesis, longevity, metabolic regulation and neurodegenerative diseases. Sirtuins, which play a role in many physiological processes such as cell cycle regulation, apoptosis, mitochondrial biogenesis, lipid metabolism, fatty acid oxidation, cellular stress response, insulin
secretion, aging, and inflammation, have been found to have a significant role in diabetes pathogenesis in recent years.
___
- 1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of
glucose and lipid metabolism. Nature. 2001;414(6865):799-
806.
- 2. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N
ve ark. Twelve-year trends in the prevalence and risk factors of
diabetes and prediabetes in Turkish adults. Eur J Epidemiol.
2013;(28):169-180.
- 3. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes
Atlas: Global estimates of the prevalence of diabetes for 2011
and 2030. Diabetes Res Clin Pract. 2011;94(3): 311-321.
- 4. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes
JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global
estimates of diabetes prevalence for 2017 and projections for
2045. Diabetes Res Clin Pract. 2018;(138):271-281.
- 5. International Diabetes Federation. IDF Diabetes Atlas, 8th
edn. Brussels, Belgium: International Diabetes Federation,
2017. http://www.diabetesatlas.org. Eriºim Tarihi: 10 Nisan
2018.
- 6. American Diabetes Association. 1. Improving care and
promoting health in populations: Standards of Medical Care
in Diabetes-2019. Diabetes Care. 2019;42(1):7-12.
- 7. Gan SK, Kriketos AD, Ellis BA, Thompson CH, Kraegen EW,
Chisholm DJ. Changes in aerobic capacity and visceral fat
but not myocyte lipid levels predict increased insulin action
after exercise in overweight and obese men. Diabetes Care.
2003;26(6):1706-1713.
- 8. Williams KV, Kelley DE. Metabolic consequences of weight
loss on glucose metabolism and insulin action in type 2
diabetes. Diabetes Obes Metab. 2000;(2):121-129.
- 9. Poulose N, Raju R. Sirtuin regulation in aging and injury.
Biochim Biophys Acta. 2015;1852(11):2442-2455.
- 10. Michan S, Sinclair D. Sirtuins in mammals: Insights into their
biological function. Biochem J. 2007;404(1):1-13.
- 11. Flick F, Lüscher B. Regulation of sirtuin function by
posttranslational modifications. Front Pharmacol. 2012;3:29.
12. Roth M, Chen WY. Sorting out functions of sirtuins in cancer.
Oncogene. 2014;33(13):1609-1620.
- 13. Chang HC, Guarente L. SIRT1 and other sirtuins in
metabolism. Trends Endocrinol Metab. 2014;25(3):138-145.
- 14. Taddei A, Roche D, Bickmore WA, Almouzni G. The effects
of histone deacetylase inhibitors on heterochromatin:
Implications for anticancer therapy? EMBO Rep.
2005;6(6):520-524.
- 15. Palmirotta R, Cives M, Della-Morte D, et al. Sirtuins and
cancer: Role in the epithelial-mesenchymal transition. Oxid
Med Cell Longev. 2016;2016:3031459.
- 16. Roth M, Chen WY. Sorting out functions of sirtuins in cancer.
Oncogene. 2014; 33(13): 1609-1620.
- 17. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst
P, Reinberg D. Human SirT1 interacts with histone H1 and
promotes formation of facultative heterochromatin. Mol Cell.
2004;16(1): 93-105.
- 18. Kitada M, Koya D. SIRT1 in type 2 diabetes: Mechanisms and
therapeutic potential. Diabetes Metab J. 2013;37(5):315-325.
- 19. Liu T, Liu PY, Marshall GM. The critical role of the class III
histone deacetylase SIRT1 in cancer. Cancer Res. 2009;69(5):
1702-1705.
- 20. Bordone L, Guarente L. Calorie restriction, SIRT1 and
metabolism: Understanding longevity. Nat Rev Mol Cell Biol.
2005;6:298-305.
- 21. Bordone L, Motta M C, Picard F, Robinson A, Jhala US, Apfeld
J, McDonagh T, Lemieux M, McBurney M, Szilvasi A, Easlon
EJ, Lin SJ, Guarente L. Sirt1 regulates insulin secretion by
repressing UCP2 in pancreatic beta cells. PLoS Biol. 2006;4(2):
e31.
- 22. Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK,
Park JW, Kwon KB, Park BH. Overexpression of SIRT1
protects pancreatic beta-cells against cytokine toxicity by
suppressing the nuclear factor-kappaB signaling pathway.
Diabetes. 2009;58:344-351.
- 23. Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi
E, Ford E, Cras-Meneur C, Permutt MA, Imai S. Increased
dosage of mammalian Sir2 in pancreatic beta cells enhances
glucose-stimulated insulin secretion in mice. Cell Metab
2005;2:105-117.
- 24. Ramsey KM, Mills KF, Satoh A, Imai S. Age-associated loss
of Sirt1-mediated enhancement of glucose-stimulated insulin
secretion in beta cell-specific Sirt1-overexpressing (BESTO)
mice. Aging Cell. 2008;7:78-88.
- 25. Frojdo S, Durand C, Molin L, Carey AL, El-Osta A, Kingwell
BA, Febbraio MA, Solari F, Vidal H, Pirola L. Phosphoinositide
3-kinase as a novel functional target for the regulation of the
insulin signaling pathway by SIRT1. Mol Cell Endocrinol.
2011;335:166-176.
- 26. Zhang J. The direct involvement of SirT1 in insulin-induced
insulin receptor substrate-2 tyrosine phosphorylation. J Biol
Chem. 2007;282:34356-34364.
- 27. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic
adaptations through the PGC-1 alpha and SIRT1 pathways.
FEBS Lett. 2008; 582(1):46-53.
- 28. Puigserver P, Spiegelman BM. Peroxisome proliferatoractivated
receptor-gamma coactivator 1 alpha (PGC-1 alpha):
Transcriptional coactivator and metabolic regulator. Endocr
Rev. 2003; 24(1):78-90.
- 29. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM,
Puigserver P. Nutrient control of glucose homeostasis
through a complex of PGC-1alpha and SIRT1. Nature. 2005;
434(7029):113-118.
- 30. Kitada M, Koya D. SIRT1 in Type 2 diabetes: Mechanisms and
therapeutic potential. Diabetes Metab J. 2013;37(5):315-325.
- 31. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid
metabolic response through hepatic sirtuin 1. Proc Natl Acad
Sci U S A. 2007; 104(31):12861-12866.
- 32. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X,
Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid
metabolism and results in hepatic steatosis and inflammation.
Cell Metab. 2009; 9(4):327-338.
- 33. Mangelsdorf DJ, Evans RM. The RXR heterodimers and
orphan receptors. Cell. 1995; 83(6):841-850.
- 34. Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, Wu
SY, Chiang CM, Veenstra TD, Kemper JK. SIRT1 deacetylates
and inhibits SREBP-1C activity in regulation of hepatic lipid
metabolism. J Biol Chem. 2010;285(44):33959-339570.
- 35. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong
T, Machado De Oliveira R, Leid M, McBurney MW, Guarente
L. Sirt1 promotes fat mobilization in white adipocytes by
repressing PPAR-gamma. Nature. 2004;429:771-776.
- 36. Qiang L, Wang L, Kon N, Zhao W, Lee S, Zhang Y, Rosenbaum
M, Zhao Y, Gu W, Farmer SR, Accili D. Brown remodeling
of white adipose tissue by SirT1-dependent deacetylation of
Pparγ. Cell. 2012;150:620-632.
- 37. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S,
Starai VJ, Avalos JL, Escalante-Semerena JC, Grubmeyer C,
Wolberger C, Boeke JD. A phylogenetically conserved NADdependent
protein deacetylase activity in the Sir2 protein
family. Proc Natl Acad Sci USA. 2000;97:6658-6663.
- 38. De Oliveira RM, Sarkander J, Kazantsev AG, Outeiro TF.
SIRT2 as a therapeutic target for age-related disorders. Front
Pharmacol, 2012; 3: 82.
- 39. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The
human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin
deacetylase. Mol Cell. 2003; 11(2): 437-444.
- 40. Rothgiesser KM, Erener S, Waibel S, Lüscher B, Hottiger MO.
SIRT2 regulates NF-κB dependent gene expression through
deacetylation of p65 Lys310. J Cell Sci. 2010; 123(Pt 24): 4251-
4258.
- 41. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt
FW, Serrano L, Sternglanz R, Reinberg D. SirT2 is a histone
deacetylase with preference for histone H4 Lys 16 during
mitosis. Genes Dev. 2006; 20(10): 1256-1261.
- 42. Gomes P, Fleming Outeiro T, Cavadas C. Emerging role of
Sirtuin 2 in the regulation of mammalian metabolism. Trends
Pharmacol Sc. 2015;36:756-768.
- 43. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte
differentiation through FoxO1 acetylation/deacetylation. Cell
Metab. 2007; 6(2): 105-114.
- 44. Wang F, Tong Q. SIRT2 suppresses adipocyte differentiation
by deacetylating FOXO1 and enhancing FOXO1’s repressive
interaction with PPARgamma. Mol Biol Cell.2009;20:801-808.
- 45. Jiang W, Wang S, Xiao M, Lin Y, Zhou L, Lei Q, Xiong Y,
Guan KL, Zhao S. Acetylation regulates gluconeogenesis by
promoting PEPCK1 degradation via recruiting the UBR5
ubiquitin ligase. Mol Cell. 2011; 43(1): 33-44.
- 46. Zhang M, Pan Y, Dorfman RG, Yin Y, Zhou Q, Huang S, Liu
J, Zhao S. Sirtinol promotes PEPCK1 degradation and inhibits
gluconeogenesis by inhibiting deacetylase SIRT2. Sci Rep.
2017;7(1):7.
- 47. Watanabe H, Inaba Y, Kimura K, Matsumoto M, Kaneko S,
Kasuga M, Inoue H. Sirt2 facilitates hepatic glucose uptake by
deacetylating glucokinase regulatory protein. Nat Commun.
2018; 9(1):30.
- 48. Han J, Wei M, Wang Q, Li X, Zhu C, Mao Y, Wei L, Sun Y,
Jia W. Association of genetic variants of SIRT1 with type 2
diabetes mellitus. Gene Expr. 2015;16(4):177-185.
- 49. Gambino R, Fanni G, Togliatto G, Ponzo V, Goitre I,
Cassader M, Brizzi MF, Bo S. Rs12778366 single nucleotide
polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol
supplementation in patients with type 2 diabetes mellitus. Acta
Diabetol. 2019;56(8):963-966.
- 50. Peng Y, Zhang G, Tang H, Dong L, Gao C, Yang X, Peng
Y, Xu Y. Influence of SIRT1 polymorphisms for diabetic
foot susceptibility and severity. Medicine (Baltimore).
2018;97(28):e11455.
- 51. Zhuanping Z, Rifang L, Qing C, Sidong C. The Association
between SIRT1 genetic variation and type 2 diabetes mellitus
is influenced by dietary intake in elderly Chinese. Iran J Public
Health. 2018;47(9):1272-1280.
- 52. Zhao Y, Wei J, Hou X, Liu H, Guo F, Zhou Y, Zhang Y, Qu
Y, Gu J, Zhou Y, Jia X, Qin G, Feng L. SIRT1 rs10823108 and
FOXO1 rs17446614 responsible for genetic susceptibility to
diabetic nephropathy. Sci Rep. 2017;7(1):10285.
- 53. Domínguez-Cruz MG, Muñoz ML, Totomoch-Serra A,
García-Escalante MG, Burgueño J, Valadez-González N,
Pinto-Escalante D, Díaz-Badillo A. Maya gene variants related
to the risk of type 2 diabetes in a family-based association
study. Gene. 2020;730:144259.
- 54. Maeda S, Koya D, Araki SI, Babazono T, Umezono T, Toyoda
M, Kawai K, Imanishi M, Uzu T, Suzuki D, Maegawa H,
Kashiwagi A, Iwamoto Y, Nakamura Y. Association between
single nucleotide polymorphisms within genes encoding
sirtuin families and diabetic nephropathy in Japanese subjects
with type 2 diabetes. Clin Exp Nephrol. 2011;15(3):381-390.
- 55. Rai E, Sharma S, Kaul S, Jain K, Matharoo K, Bhanwer AS,
Bamezai RN. The interactive effect of SIRT1 promoter region
polymorphism on type 2 diabetes susceptibility in the North
Indian population. PLoS One. 2012;7(11):e48621.
- 56. Dong Y, Guo T, Traurig M, Mason CC, Kobes S, Perez J,
Knowler WC, Bogardus C, Hanson RL, Baier LJ. SIRT1 is
associated with a decrease in acute insulin secretion and a sex
specific increase in risk for type 2 diabetes in Pima Indians.
Mol Genet Metab. 2011;104(4):661-665.
- 57. Liu T, Yang W, Pang S, Yu S, Yan B. Functional genetic
variants within the SIRT2 gene promoter in type 2 diabetes
mellitus. Diabetes Res Clin Pract. 2018;137:200-207.
- 58. Zhou S, Tang X, Chen HZ. Sirtuins and Insulin Resistance.
Front Endocrinol (Lausanne). 2018;9:748.